The assessment of coronary artery disease severity, progression, and regression has historically been performed using quantitative coronary angiography (QCA); it is well known, however, that the degree of atherosclerotic plaque is underestimated by QCA. In contrast, intravascular ultrasound has been shown to define the plaque and its composition more accurately. It is not clear how well serial intravascular ultrasound measurements compare to serial QCA measurements. The study by Berry et al in this issue of Circulation compared intravascular ultrasound and QCA at baseline and after 24 months in 525 and 432 patients, respectively. A significant correlation was seen between baseline measures of lumen dimensions using the 2 techniques, but weak correlations between plaque volume and luminal narrowing were observed over time. Disease progression by QCA was associated with a significant increase in plaque volume on intravascular ultrasound, however. While these techniques correlate with each other, the relationship is not strong enough to consider them as equivalent. See p 1851 (editorial p 1824).
A PROSPECTIVE STUDY OF TRANS FATTY ACIDS IN ERYTHROCYTES AND RISK OF CORONARY HEART DISEASE, by Sun et al.
Studies have suggested that the type of fat consumed can contribute to cardiovascular disease; specifically, intake of trans fats leads to increased vascular risk. Is it possible to measure this risk from a blood-derived marker? In the current issue of Circulation, Sun and colleagues measured trans fatty acids from erythrocytes in selected participants from the Women's Health Study. They found that higher total trans fatty acid content in erythrocytes was associated with an elevated risk of developing coronary heart disease even after adjusting for covariates. It will be interesting to determine in future studies if modification of this marker is associated with decreased cardiovascular risk. See p 1858.
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL OF THE EFFECT OF COMBINED THERAPY WITH DEFEROXAMINE AND DEFERIPRONE ON MYOCARDIAL IRON IN THALASSEMIA MAJOR USING CARDIOVASCULAR MAGNETIC RESONANCE, by Tanner et al.
Recent studies have documented that cardiovascular magnetic resonance using a T2* acquisition sequence can provide an index that quantifies myocardial and hepatic iron content in patients with ␤-thalassemia major, an important advance allowing for a noninvasive marker that can reflect treatment effect of chelating agents. In this issue of Circulation, Tanner et al take advantage of this technique by conducting a clinical trial that examines the effect of adding the oral iron chelator deferiprone on a group of ␤-thalassemia major patients with cardiovascular magnetic resonance evidence of myocardial iron, despite standard maintenance subcutaneous deferoxamine chelation therapy. In a double-blind, randomized, placebo-controlled setting, the authors report that the addition of deferiprone was associated with a reduction in myocardial iron, an increase in ejection fraction, improved endothelial function, and reduction in serum ferritin. As myocardial dysfunction from iron overload in ␤-thalassemia major contributes substantially to long-term morbidity and mortality in ␤-thalassemia major, these data have substantial treatment implications for this challenging group of patients. See p 1876. 
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